News und Analysen

Stock markets looked poised to continue their winning ways on Wednesday morning, as stock index futures were higher across the board. Investors will get a look today at the latest thought process

Pharmaceutical giant Merck (NYSE: MRK) has delivered excellent returns to its shareholders over the past 12 months, as last year's downturn did little to slow the drugmaker. The company's solid

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) are both among the largest biopharmaceutical businesses in the world, but their growth prospects aren't exactly the same. Nonetheless, the pair handily

Investing for income may never be the most exciting investment strategy in the world. But as long as a company doesn't cut or suspend its dividend, it can be a profitable approach -- and some

Merck (NYSE: MRK) has performed poorly in the stock market this year, with the drugmaker's shares down by 5%. But zooming out helps put a different spin on this story as the pharmaceutical giant has

Image source: The Motley Fool.

Merck (NYSE: MRK)Q2 2023 Earnings CallAug 01, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Fresenius Medical Care (NYSE: FMS) were up more than 11% for the week as of Friday at 1:30 p.m. ET, according to data provided by S&P Global Market Intelligence. The German healthcare

Whether you're saving for retirement, want to set aside money for travel, or just want to give yourself a raise, dividend stocks can help give you some extra income to accomplish those goals. Plus

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The war on drug

Shares of NovoCure (NASDAQ: NVCR) were crashing 29.6% lower as of 10:19 a.m. ET on Tuesday. The steep decline came after the company announced data for its Tumor Treating Fields (TTFields) therapy

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had

Affordably priced shares -- typically seen as those trading under $30 on a per-share basis -- are a rarity among large companies with stable long-term growth prospects. That's because the market

Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. What's interesting